First Scientific Presentations On ViewRay's MRIdian Linac Technology
CLEVELAND, Aug. 8, 2016 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), makers of the world's first and only clinical MRI-guided radiation therapy system, announced today highlights from the recent 2016 Annual Meeting of the American Association of Physicists in Medicine (AAPM), which featured extensive clinical experience with the company's MRIdian System, including the first data from the company's MRIdian linear accelerator (Linac) technology, which is currently under development.
For the first time, researchers from the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis and the University of California, Los Angeles gave presentations on the MRIdian Linac technology. The oral presentations, given during the "MR-Linac Design" session at the AAPM meeting, focused on the design and characteristics of the MR-guided Linac technology and summarized data from recent testing performed in ViewRay's Mountain View, Calif. facility. Speakers highlighted ViewRay's patented magnetic and radio frequency shielding technology that ensures minimal interaction between the linear accelerator and the MRI magnetic field, addressing the fundamental incompatibility of the two technologies that has previously made it impossible to combine them. Quantitative data were presented demonstrating the ability of this compact system to image and deliver radiation simultaneously.
ViewRay's MRIdian System was also featured in oral presentations in the "Imaging Assessment of Treatment Response" session at the AAPM meeting. Researchers from the University of California, Los Angeles have successfully developed a diffusion MRI technique on the MRIdian System, which quantifies tissue density inside tumors to gauge their response to radiation.
The research presented demonstrates MRIdian's capabilities for on-table anatomical and biological imaging during the course of radiation therapy, reinforcing its role in delivering personalized, adaptive cancer treatment.
"It's exciting to have the past few years of MRIdian clinical experience and the progress being made on the MRIdian Linac technology showcased at AAPM," said Chris A. Raanes, President and Chief Executive Officer of ViewRay. "With so many impactful MRIdian presentations on the program this year, we saw increased traffic to the ViewRay booth and overwhelming attendance at our presentations. I am very pleased to see the reaction to the first scientific data on our developing Linac technology."
In ViewRay's booth, MRIdian users from University of California, Los Angeles; University of Miami; Washington University in St. Louis; and University of Wisconsin, Madison, presented on their first-hand clinical experience treating cancer patients with the MRIdian System. To view videos of these MRIdian user presentations from AAPM, please visit http://www.viewray.com/aapm_2016.htm.
The MRIdian Linac technology is presently available for non-clinical research use only. ViewRay expects to complete its U.S. FDA and European CE Mark submissions for MRIdian Linac in the second half of 2016.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the expected completion of ViewRay's U.S. FDA and European CE Mark submissions for MRIdian Linac. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the MRIdian Linac, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/first-scientific-presentations-on-viewrays-mridian-linac-technology-300310197.html
SOURCE ViewRay, Inc.
